Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD.